| Revenue growth | 15% YoY growth to 304 Cr in Q1 FY27. |
|---|---|
| Margins | Gross margin improved 3% points YoY to 33%. |
| Demand visibility | Cyclical demand in regulated markets; winter season expected to be better. |
| Management confidence | Cautiously optimistic; focusing on execution and cost discipline. |
Growth
Revenue grew 15% YoY to 304 Cr; EBITDA improved significantly to 25 Cr from 10 Cr YoY.
Outlook
Commissioning of 7-ACA and Cefiderocol projects by FY27; targeting high utilization in first year.
Risks
Industry overcapacity, cut-throat competition in non-regulated markets, and execution risks in large-scale fermentation projects like 7-ACA.
Last quarter's promises, checked
Delivered
- Targeted 10-15% base business growth → delivered 15% (= BEAT)
- Guided 12% EBITDA margin for base business → delivered 12.3% (= BEAT)
- Targeted Q1 FY27 recovery after FY26 pressure → delivered 304 Cr revenue (= BEAT)
Partly delivered
- 7-ACA project execution race against time → on track for FY27 commissioning (= PARTIAL)
Missed
- Targeted signing one Enmetazobactam deal by June 2026 → delivered 0 signed deals (= MISS)
Earnings Call Transcript filed with NSE, NSE: ORCHPHARMA. Summary written with AI assistance from the document.
Orchid Pharma Ltd: key numbers
- Share price
- ₹1,064.90
- Market cap
- ₹6,377 Cr
- Revenue (annual)
- ₹811.3 Cr
- Net profit (annual)
- ₹20.55 Cr
- P/E (TTM)
- 735.8×Sector 50.4×
- Promoter holding
- 69.84%+0.00% QoQ
- FII holding
- 0.80%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Orchid Pharma Ltd
All →Orchid Pharma Capital Structure Change
Orchid Pharma Limited received trading approval for 4,45,86,052 equity shares issued under its NCLT-sanctioned scheme of amalgamation, effective September 23, 2026.
Orchid Pharma Acquisition
Orchid Pharma purchased land in Patibulum Village, Kancheepuram District. This transaction concludes the previous lease arrangement with DBS Bank regarding the property.
Orchid Pharma Annual Report
Orchid Pharma has filed its Annual Report for the financial year 2025-26, which includes the notice for the company's 33rd Annual General Meeting.
Orchid Pharma Annual General Meeting
Orchid Pharma Limited has issued the notice for its 33rd Annual General Meeting scheduled for September 29, 2026, to conduct ordinary and special business.
Orchid Pharma Management Change
Orchid Pharma Limited announced the redesignation of Mr. Arjun Dhanuka as Executive Director and the appointment of M/s. J Karthikeyan & Associates as Cost Auditors.
Orchid Pharma Board Meeting Outcome
Orchid Pharma appointed a cost auditor and designated Mr. Arjun Dhanuka as a Whole-Time Director. The board also set arrangements for the upcoming 33rd Annual General Meeting.